Active immunization of metastatic melanoma patients with interleukin-2- transduced allogeneic melanoma cells: Evaluation of efficacy and tolerability

Cancer Immunology Immunotherapy

Volumn 44, Issue 4, 1997, Pages 197-203

  Belli, Filiberto ^a   Arienti, Flavio ^a   Sulé Suso, Josep ^a,c   Clemente, Claudio ^a,d   Mascheroni, Luigi ^a   Cattelan, Alessandro ^b   Sanantonio, Cristina ^b   Gallino, Gian Francesco ^a   Melani, Cecilia ^a   Rao, Stefania ^a   Colombo, Mario P ^a   Maio, Michele ^b   Cascinelli, Natale ^a   Parmiani, Giorgio ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^c UNIVERSITY HOSPITALS OF NORTH MIDLANDS NHS TRUST   (United Kingdom)

^d Casa di Cura S Pio X   (Italy)

Author keywords

Gene therapy; Melanoma; Vaccination

Indexed keywords

INTERLEUKIN 2;

ADULT; AGED; ALLOGRAFT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; GENE THERAPY; HUMAN; IMMUNIZATION; MALE; MELANOMA; METASTASIS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; VACCINATION;

ADULT; AGED; CELL TRANSPLANTATION; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HLA-A2 ANTIGEN; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; IMMUNOTHERAPY, ACTIVE; INJECTIONS, SUBCUTANEOUS; INTERLEUKIN-2; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; MELANOMA; MIDDLE AGED; SKIN NEOPLASMS; SOFT TISSUE NEOPLASMS; TIME FACTORS; TRANSDUCTION, GENETIC; TRANSPLANTATION, HOMOLOGOUS; TUMOR CELLS, CULTURED;

EID: 8544266091     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002620050373     Document Type: Article

References (25)

1. Antoine E, Rixe O, Vuillemin E, Bazer PA, Thill L, Franks R, Auclerc G, Soubrane C, Bauzet O, Weil M (1993) Sequential chemoimmunotherapy with cisplatin, interleukin-2 and Interferon 2α for metastatic melanoma. J Clin Oncol 11:2173
2. Arienti F, Belli F, Rivoltini L, Gambacorti-Passerini C, Furlan L, Mascheroni L, Prada A, Rizzi M, Marchesi E, Vaglini M, Parmiani G, Cascinelli N (1993) Adoptive immunotherapy of advanced melanoma patients with interleukin-2 (IL-2) and tumor-infiltrating lymphocytes selected in vitro with low doses of IL-2. Cancer Immunol Immunother 36:315
3. Arienti F, Sulé-Suso J, Melani C, Maccalli C, Belli F, Illeni MT, Anichini A, Cascinelli N, Colombo MP, Parmiani G (1994) Interleukin-2 gene transduced human melanoma cells efficiently stimulate MHC-unrestricted and MHC-restricted autologous lymphocytes. Hum Gene Ther 5:139
4. Arienti F, Sulé-Suso J, Belli F, Mascheroni L, Rivoltini L, Melani C, Maio M, Cascinelli N, Colombo MP, Parmiani G (1996) Limited anti-tumor T-cell response in melanoma patients vaccinated with interleukin-2 gene-transduced allogeneic melanoma cells. Hum Gene Ther 7:1955
5. Boon T, Bruggen van der (1996) Human tumor antigens recognized by T lymphocytes. J Exp Med 183:725
6. Cascinelli N, Belli F, Marchini S, Marolda R, Prada A, Sciorelli G, Villani F, Gambacorti-Passerini C, Galatzka A, Parmiani G (1989) A phase II study of the administration of recombinant interleukin-2 (rIL-2) plus lymphokine-activated killer (LAK) cells in stage IV melanoma patients. Tumori 75:233
7. Colombo MP, Forni G (1994) Cytokine gene transfer in tumor inhibition and tumor therapy: where are we now? Immunol Today 15:48
8. Ferradini L, Mackensen A, Genevée C, Bosq J, Duvillard P, Avril MF, Hercend T (1993) Analysis of T cell receptor variability in tumor-infiltrating lymphocytes from a human regressive melanoma. J Clin Invest 91:1183
9. Ferrone S, Marincola FM (1995) Loss of HLA class 1 antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. Immunol Today 16:487
10. Kirkwood JM (1991) Studies of interferons in the therapy of melanoma. Semin Oncol 18:83
11. Kradin RL, Kurnick JT, Lazarus PS, Preffer FI, Dubinett SM, Pinto CE, Gifford J, Davidson E, Grove B, Callahan RJ, Strauss HW (1989) Tumor-infiltrating lymphocytes and interleukin-2 in treatment of advanced cancer. Lancet 1:577
12. Marincola FM, Hijazi YM, Fetsch P, Salgaller ML, Rivoltini L, Cormier J, Simonis TB, Duray PH, Herlyn M, Kawakami Y, Rosenberg SA (1996) Analysis of expression of the melanoma-associated antigens MART-1 and gp100 in metastatic melanoma cell lines and in in situ lesions. J Immunother 19:192
13. Mitchell MS (1995) Active specific immunotherapy of melanoma. Br Med Bull 51:631
14. Natali PG, Nicotra MR, Bigotti A, Venturo I, Mercenaro L, Giacomini P, Russo C (1989) Selective changes in expression of HLA class 1 polymorphic determinants in human solid tumors. Proc Natl Acad Sci USA 86:6719
15. Parmiani G, Colombo MP (1995) Somatic gene therapy of human melanoma: preclinical studies and early clinical trials. Melanoma Res 5:259-301
16. Parmiani G, Anichini A, Fossati G (1990) Cellular immune response against autologous human malignant melanoma: are in vitro studies providing a framework for a more effective immunotherapy? J Natl Cancer Inst 82:361
17. Parmiani G, Colombo MP, Melani C, Arienti F (1997) Cytokine gene transduction in the immunotherapy of cancer. Adv Pharmacol (in press)
18. Richards JN, Mehta AN, Ramming K, Skosey P (1992) Sequential chemoimmunotherapy in the treatment of metastatic melanoma. J Clin Oncol 10:1938
19. Rivoltini L, Kawakami Y, Sakaguchi K, Southwood S, Sette A, Robbins PF, Marincola FM, Salgaller ML, Yannelli JR, Appella E, Rosenberg SA (1995) Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1. J Immunol 154:2257
20. Rivoltini L, Loftus DJ, Barracchini K, Arienti F, Mazzocchi A, Biddison WE, Salgaller ML, Appella E, Parmiani G, Marincola FM (1996) Binding and presentation of peptides derived from melanoma antigens MART-1 and gp100 by HLA-A2 subtypes: implications for peptide-based immunotherapy. J Immunol 156:3882
21. Rosenberg SA, Yannelli JR, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, Seipp CA, Einhorn JH, White DE (1994) Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst 86:1159
22. Schmidt W, Schweighoffer T, Herbst E, Maass G, Berger M, Schilcher F, Schaffner G, Birnstiel M (1995) Cancer vaccines: the interleukin-2 dosage effect. Proc Natl Acad Sci USA 92:4711
23. Sensi ML, Salvi S, Castelli C, Maccalli C, Mazzocchi A, Mortarini R, Nicolini G, Herlyn M, Parmiani G, Anichini A (1993) T Cell Receptor (TCR) structure of autologous melanoma-reactive. Cytotoxic T Lymphocyte (CTL) clones: tumor infiltrating lymphocytes overexpress in vivo the TCR beta-chain sequence used by an HLA-A2-restricted and melanocyte-lineage-specific CTL clone. J Exp Med 178:1231
24. Uchiyama A, Hoon DSB, Morisaki T, Kaneda T, Yuzuki DH, Morton DL (1993) Transfection of interleukin-2 gene into human melanoma cells augments cellular immune response. Cancer Res 53:949
25. Veronesi U, Adamus J, Aubert C, Bajetta E, Beretta G, Bonadonna G, Bufalino R, Cascinelli N, Cocconi G, Durant J, De Marsillac J, Ikonopisov RL, Kiss B, Lejeune F, Mackie R, Madej G, Mulder H, Mechl Z, Milton GW, Morabito A, Peter H, Priario J, Paul E, Rumke P, Sertoli R, Tomin RA (1982) Randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma. N Engl J Med 307:913